Skip to search formSkip to main contentSkip to account menu

1 ML canakinumab 150 MG/ML Injection [Ilaris]

Known as: CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Ilaris], Ilaris 150 MG per 1 ML Injection, ILARIS 150 MG in 1 ML Injection 
National Institutes of Health

Related topics

Related topics

7 relations
HistidineInjectionMannitolPolysorbate 80

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Canakinumab (ILARIS®) in cryopyrin-associated periodic syndrome (CAPS)patients below 2 years of age: Review of four cases and literature.
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)